The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...